NASDAQ:ATRA Atara Biotherapeutics Q3 2025 Earnings Report $8.09 -0.42 (-4.94%) As of 08/14/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Atara Biotherapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.83Beat/MissBeat by +$0.51One Year Ago EPSN/AAtara Biotherapeutics Revenue ResultsActual Revenue$3.45 millionExpected Revenue$2.74 millionBeat/MissBeat by +$714.00 thousandYoY Revenue GrowthN/AAtara Biotherapeutics Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time9:00AM ETUpcoming EarningsAtara Biotherapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Atara Biotherapeutics Earnings HeadlinesAtara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational ProgressAugust 12 at 6:30 PM | finance.yahoo.comAtara Biotherapeutics (ATRA) Expected to Release Earnings on MondayAugust 9, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 15 at 1:00 AM | Chaikin Analytics (Ad)Atara Biotherapeutics (NASDAQ:ATRA) Cut to Sell at Wall Street ZenAugust 8, 2026 | americanbankingnews.comAtara Biotherapeutics Announces $15 Million Registered Direct OfferingJuly 7, 2026 | businesswire.comQuetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic LeukemiaJune 11, 2026 | globenewswire.comSee More Atara Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email. Email Address About Atara BiotherapeuticsAtara Biotherapeutics (NASDAQ:ATRA) is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders. The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers. In addition, Atara is advancing multiple earlier-stage programs, including ATA188 for progressive multiple sclerosis and ATA227 for autoimmune indications, each harnessing the company’s expertise in antigen-specific T-cell biology. Atara’s pipeline is supported by manufacturing and process development capabilities aimed at delivering scalable, cryopreserved cell therapies for global distribution. Founded in 2012, Atara Biotherapeutics has built a diversified clinical portfolio and established collaborations to advance its therapies across North America, Europe and Asia. The company’s leadership team combines expertise in cell therapy development, regulatory affairs and commercial strategy, guided by President and Chief Executive Officer Pascal Touchon. Through ongoing clinical studies and strategic partnerships, Atara aims to address unmet medical needs in oncology and autoimmune disease with its off-the-shelf T-cell products.View Atara Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsBack From Orbit, Intuitive Machines' Share Price Enters the Buy ZoneCerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More Divided Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
